Real‐world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment‐naive, genotype 1 hepatitis C‐infected patients

Lisa I. Backus, Pamela S. Belperio, Troy A. Shahoumian, Timothy P. Loomis, Larry A. Mole – 26 April 2016 – Real‐world effectiveness data are needed to inform hepatitis C virus (HCV) treatment decisions. The uptake of ledipasvir/sofosbuvir (LDV/SOF) regimens across health care settings has been rapid, but variations often occur in clinical practice. The aim of this study was to assess sustained virologic response (SVR) of LDV/SOF±ribavirin (RBV) in routine medical practice.

Cell‐specific overactivation of nuclear erythroid 2 p45‐related factor 2–mediated gene expression in myeloid cells decreases hepatic ischemia/reperfusion injury

Lung‐Yi Lee, Calvin Harberg, Kristina A. Matkowskyj, Shelly Cook, Drew Roenneburg, Sabine Werner, Delinda A. Johnson, Jeffrey A. Johnson, David P. Foley – 26 April 2016 – Hepatic ischemia/reperfusion injury (IRI) is an unavoidable consequence of liver transplantation that can lead to postoperative hepatic dysfunction. Myeloid cells that include Kupffer cells, monocytes, and neutrophils contribute to the inflammatory response and cellular injury observed during hepatic IRI.

Intention‐to‐treat survival analysis of hepatitis C virus/human immunodeficiency virus coinfected liver transplant: Is it the waiting list?

Juan J. Araiz, M. Trinidad Serrano, Francisco A. García‐Gil, Elena M. Lacruz, Sara Lorente, José I. Sánchez, Miguel A. Suarez – 26 April 2016 – In human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients, the accelerated severity of liver disease, associated comorbidities, and mortality on the waiting list could change the possibility and results of liver transplantation (LT). Intention‐to‐treat survival analysis (ITTA) can accurately estimate the applicability and efficacy of LT.

Subscribe to